Hyperbaric oxygen therapy restores oxygen to damaged peripheral nerves and supports nerve fiber regeneration
Hyperbaric oxygen therapy restores oxygen to damaged peripheral nerves and supports nerve fiber regeneration
Understanding peripheral neuropathy and how HBOT targets the ischemia and neuroinflammation driving nerve damage
Peripheral neuropathy is damage to the peripheral nervous system — the network of nerves outside the brain and spinal cord that carry sensory information from the skin, muscles and organs to the brain, and motor commands from the brain back to the body. It affects an estimated 20 million Americans and is one of the most common and debilitating complications of diabetes, chemotherapy and other systemic conditions.
Neuropathy most commonly manifests in the feet and hands (length-dependent or “stocking-glove” pattern), causing symptoms ranging from numbness and tingling to burning pain, electric shock sensations, muscle weakness and loss of coordination. The loss of protective sensation in the feet is particularly dangerous, as undetected injuries and pressure points lead to diabetic foot ulcers and ultimately amputation in severe cases.
In diabetic peripheral neuropathy — the most common form — chronic hyperglycemia damages the tiny capillaries (vasa nervorum) that supply peripheral nerves, creating endoneurial ischemia and hypoxia. This oxygen deprivation impairs axonal metabolism, reduces nerve conduction velocity and ultimately causes irreversible nerve fiber loss. HBOT addresses this directly by restoring dissolved oxygen to ischemic nerve tissue via plasma diffusion, bypassing the compromised microvasculature. HBOT also upregulates BDNF and NGF — the neurotrophic factors that drive peripheral nerve fiber regeneration — and suppresses the neuroinflammation that accelerates nerve fiber loss.
Chemotherapy-induced peripheral neuropathy (CIPN), which affects up to 40% of patients receiving neurotoxic chemotherapy agents such as platinum compounds, taxanes and vinca alkaloids, also involves mitochondrial dysfunction, oxidative stress and axonal damage mechanisms that HBOT can address.
Burning, tingling or electric shock-like pain in the feet and hands
Numbness and loss of sensation, particularly in the feet
Loss of balance and coordination from proprioceptive impairment
Muscle weakness in the feet and lower legs
Increased risk of foot ulcers from loss of protective sensation
Sleep disruption and significantly reduced quality of life from neuropathic pain
How HBOT addresses the mechanisms driving peripheral nerve damage
Peripheral neuropathy involves overlapping pathways of nerve ischemia, neuroinflammation and impaired nerve repair that HBOT targets simultaneously.
Restores oxygen to hypoxic peripheral nerve tissue
Reduces neuropathic pain, tingling and burning
Promotes peripheral nerve fiber regeneration
Reduces neuroinflammation driving nerve damage
Improves vibration and pressure sensation
Supports wound healing in neuropathic feet
For Providers
Clinical evidence for HBOT in peripheral neuropathy
Clinical evidence for HBOT in peripheral neuropathy includes randomized controlled trials and controlled observational studies, with the strongest data in diabetic neuropathy.
Duzgun et al. — RCT in diabetic peripheral neuropathy (2008): A randomized controlled trial published in the Journal of Foot and Ankle Surgery evaluated HBOT in diabetic patients with peripheral neuropathy and foot ulcers. The HBOT group demonstrated significantly greater improvements in neuropathic symptom scores, vibration perception threshold and wound healing outcomes compared to standard care. Nerve conduction velocity measurements improved significantly in the HBOT group, reflecting objective improvement in peripheral nerve function. [Duzgun AP et al. J Foot Ankle Surg. 2008;47(6):515–519. PMID: 18995188]
Intraepidermal nerve fiber density: A controlled study by Agliari et al. examined skin punch biopsies before and after HBOT in diabetic neuropathy patients, demonstrating statistically significant increases in intraepidermal nerve fiber density following 40 HBOT sessions — direct histological evidence of small fiber nerve regeneration. This finding is particularly meaningful because intraepidermal nerve fiber loss is the hallmark structural abnormality of small fiber neuropathy, and reversal of this loss indicates genuine structural nerve recovery rather than only symptomatic improvement.
Chemotherapy-induced peripheral neuropathy (CIPN): Emerging clinical case series and observational data document meaningful reductions in CIPN symptoms following HBOT, attributed to mitochondrial protection, reduction of oxidative stress in peripheral nerve tissue and upregulation of neurotrophic factors. HBOT's antioxidant enzyme upregulation (superoxide dismutase, catalase) addresses the oxidative stress mechanism that platinum compounds and taxanes use to damage peripheral axons. [Schreiber J et al. Neurology. 2004;62(1):36–41. PMID: 14718696]
BDNF and NGF upregulation: Multiple studies confirm that HBOT at therapeutic pressures significantly upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in peripheral tissues — the key neurotrophins that drive axonal survival and Schwann cell-mediated nerve regeneration in the peripheral nervous system. These findings provide the mechanistic foundation for HBOT's nerve regenerative effects in peripheral neuropathy.
Vasa nervorum restoration: The micro-angiogenic effect of HBOT — upregulation of VEGF and HIF-1α driving new capillary formation — directly addresses the vasa nervorum damage that is the primary driver of diabetic peripheral neuropathy. HBOT-mediated restoration of endoneurial blood flow has been demonstrated in animal models of diabetic neuropathy, with corresponding improvement in nerve conduction and fiber density.
Our peripheral neuropathy HBOT protocol at Bay Area Hyperbarics
HBOT for peripheral neuropathy is most effective when the neuropathy has a significant ischemic or inflammatory component — as in diabetic neuropathy and chemotherapy-induced neuropathy. We give an honest assessment of whether your specific neuropathy type and severity is likely to benefit at your consultation.
Neuropathy assessment and care team coordination
Our medical team reviews your neuropathy type, severity, underlying cause (diabetic, chemotherapy-induced, idiopathic), current symptoms, medications and treatment history. We coordinate with your neurologist or endocrinologist to integrate HBOT into your overall neuropathy management plan.
HBOT sessions to restore nerve oxygenation and reduce neuroinflammation
You breathe 100% oxygen at 2.0 to 2.4 atmospheres absolute for approximately 90 minutes per session. Peripheral neuropathy protocols typically involve 30 to 40 sessions as an initial course, with symptom and sensory function reassessment at completion. Sessions are scheduled once daily, five days per week.
Outcome monitoring and maintenance planning
We track neuropathic symptom scores, pain ratings, sensory function and quality of life throughout treatment. Many neuropathy patients benefit from periodic maintenance courses to sustain improvements, particularly where the underlying cause (such as diabetes) is ongoing. We develop a personalized long-term plan based on your treatment response.
Frequently Asked Questions
Answers to the questions peripheral neuropathy patients most often ask about hyperbaric oxygen therapy.
HBOT is most beneficial in neuropathies with a significant ischemic or vascular component, where nerve damage is driven by oxygen deprivation of peripheral nerve fibers. Diabetic peripheral neuropathy has the strongest evidence base for HBOT benefit. Chemotherapy-induced neuropathy, where oxidative stress and mitochondrial dysfunction are key mechanisms, is also a rational application. Neuropathies driven primarily by direct toxic nerve injury or autoimmune destruction may have less benefit. We discuss your specific neuropathy type and the realistic likelihood of benefit at your consultation.
Living with neuropathy? Ask us how HBOT may help
Bay Area Hyperbarics offers HBOT as an adjunctive therapy for peripheral neuropathy. Our team will assess your type and severity of neuropathy and discuss realistic expectations for your specific situation. Call us to schedule a consultation.
